These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 25373851

  • 1. Pentraxin-3 concentrations in stable coronary artery disease depend on the clinical presentation.
    Hudzik B, Danikiewicz A, Szkodzinski J, Polonski L, Zubelewicz-Szkodzinska B.
    Eur Cytokine Netw; 2014; 25(3):41-5. PubMed ID: 25373851
    [Abstract] [Full Text] [Related]

  • 2. Plasma pentraxin 3 may be a more sensitive marker of inflammatory response than high-sensitivity C-reactive protein after bare-metal stent compared to drug-eluting stent implantation.
    Hudzik B, Szkodzinski J, Pietka-Rzycka A, Danikiewicz A, Wojnar R, Lekston A, Polonski L, Zubelewicz-Szkodzinska B.
    J Interferon Cytokine Res; 2013 May; 33(5):280-4. PubMed ID: 23414296
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of plasma pentraxin-3 levels in patients with stable coronary artery disease after drug-eluting stent implantation.
    Haibo L, Xiaofang G, Chunming W, Jie Y, Guozhong C, Limei Z, Yong C, Yu F, Yingchun B, Wangjun Y, Junbo G.
    Mediators Inflamm; 2014 May; 2014():963096. PubMed ID: 25538378
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pentraxin 3 and C-reactive protein in severe meningococcal disease.
    Sprong T, Peri G, Neeleman C, Mantovani A, Signorini S, van der Meer JW, van Deuren M.
    Shock; 2009 Jan; 31(1):28-32. PubMed ID: 18650775
    [Abstract] [Full Text] [Related]

  • 7. Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease.
    Hollan I, Bottazzi B, Cuccovillo I, Førre ØT, Mikkelsen K, Saatvedt K, Almdahl SM, Mantovani A, Meroni PL, Feiring Heart Biopsy Study Group.
    Arthritis Care Res (Hoboken); 2010 Mar; 62(3):378-85. PubMed ID: 20391484
    [Abstract] [Full Text] [Related]

  • 8. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials.
    Latini R, Gullestad L, Masson S, Nymo SH, Ueland T, Cuccovillo I, Vårdal M, Bottazzi B, Mantovani A, Lucci D, Masuda N, Sudo Y, Wikstrand J, Tognoni G, Aukrust P, Tavazzi L, Investigators of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and GISSI-Heart Failure (GISSI-HF) trials.
    Eur J Heart Fail; 2012 Sep; 14(9):992-9. PubMed ID: 22740508
    [Abstract] [Full Text] [Related]

  • 9. Plasma pentraxin 3 is a more potent predictor of endothelial dysfunction than high-sensitive C-reactive protein.
    Yasunaga T, Ikeda S, Koga S, Nakata T, Yoshida T, Masuda N, Kohno S, Maemura K.
    Int Heart J; 2014 Sep; 55(2):160-4. PubMed ID: 24632958
    [Abstract] [Full Text] [Related]

  • 10. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris.
    Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, Sagara M, Miyamoto K, Satoh H, Kohno I, Kurata T, Ota H, Mantovani A, Hamakubo T, Daida H, Kodama T.
    Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):161-7. PubMed ID: 17095712
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. PENTRAXIN 3 AS A NEW CARDIOVASCULAR MARKER IN ADRENAL ADENOMAS.
    Kizilgul M, Beysel S, Ozcelik O, Kan S, Apaydin M, Caliskan M, Ucan B, Sencar E, Ozdemir S, Cakal E.
    Endocr Pract; 2017 Jun; 23(6):662-668. PubMed ID: 28332877
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases.
    Norata GD, Garlanda C, Catapano AL.
    Trends Cardiovasc Med; 2010 Feb; 20(2):35-40. PubMed ID: 20656213
    [Abstract] [Full Text] [Related]

  • 15. Pentraxin-3 expression in acute renal allograft rejection.
    Imai N, Nishi S, Yoshita K, Ito Y, Osawa Y, Takahashi K, Nakagawa Y, Saito K, Takahashi K, Narita I.
    Clin Transplant; 2012 Jul; 26 Suppl 24():25-31. PubMed ID: 22747472
    [Abstract] [Full Text] [Related]

  • 16. Pentraxin-3 as a local inflammatory marker in chronic spontaneous urticaria.
    Kasperska-Zajac A, Grzanka A, Misiolek M, Mazur B, Machura E.
    Cytokine; 2015 Dec; 76(2):566-568. PubMed ID: 25982553
    [Abstract] [Full Text] [Related]

  • 17. Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial.
    Miyazaki T, Chiuve S, Sacks FM, Ridker PM, Libby P, Aikawa M.
    PLoS One; 2014 Dec; 9(4):e94073. PubMed ID: 24705587
    [Abstract] [Full Text] [Related]

  • 18. Is pentraxin 3 a new cardiovascular risk marker in polycystic ovary syndrome?
    Sari U, Kaygusuz I, Kafali H.
    Gynecol Obstet Invest; 2014 Dec; 78(3):173-8. PubMed ID: 25011417
    [Abstract] [Full Text] [Related]

  • 19. Relationship Between Plasma Pentraxin 3 Concentration and Platelet Indices in Patients With Stable Coronary Artery Disease.
    Korzonek-Szlacheta I, Danikiewicz A, Szkodziński J, Nowak J, Lekston A, Gąsior M, Zubelewicz-Szkodzińska B, Hudzik B.
    Angiology; 2018 Mar; 69(3):264-269. PubMed ID: 28946774
    [Abstract] [Full Text] [Related]

  • 20. Different distribution of pentraxin 3 and C-reactive protein in coronary atherosclerotic plaques.
    Matsuura Y, Hatakeyama K, Imamura T, Tsuruda T, Shibata Y, Kodama T, Kitamura K, Asada Y.
    J Atheroscler Thromb; 2012 Mar; 19(9):837-45. PubMed ID: 22785134
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.